Programme


Oxford Programme – Monday 19th November 2018
09:00 – 10:00 Arrivals, coffee & badge collection
10:00 – 10:15 Chair’s opening
Professor Anna Schuh
Associate Professor, Director of Molecular Diagnostics, Honorary Consultant Haematologist, Department of Oncology, University of Oxford
10:15 – 10:45 Overview of the changing diagnostic landscape in the UK
Helene Dreau
Principal Clinical Scientist, Oxford University Hospitals NHS Trust
10:45 – 11:15 Audit of NGS Service in Oxford
Doriane Cavalieri
Clinical research fellow, Department of Oncology, University of Oxford, UK; Interne DES hematologie clinique, CHU de Clermont-Ferrand, France
11:15 – 11:35 Break
11:35 – 12:05 Presentation of the Genomics England CLL Pilot data analysis with a focus on genomics complexity
Kate Ridout
High-throughput Sequencing Bioinformatician, Department of Oncology, University of Oxford
12:05 – 12:50 MLL: WGS and WTS Programme Update
Dr Manja Meggendorfer
MLL Munich Leukemia Laboratory, Munich, Germany
12:50 – 13:45 Lunch
13:45 – 14:15 Using Nanopore technology to risk-stratify patients with CLL
Adam Burns
Post-doctoral Researcher, Health Education England/ Genomics England Genomic Medicine Fellow, Department of Oncology, University of Oxford
14:15 – 14:45 Risk stratification in early asymptomatic clonal B-cell disorders
Niamh Appleby
Health Education England/ Genomics England Genomic Medicine Fellow, Department of Oncology, University of Oxford
14:45 – 15:15 Application of cell-free DNA technology to aggressive lymphoid malignancies
Laura Lopez
Clinical Scientist with Bioinformatics, Department of Oncology, University of Oxford
Niamh Appleby
Health Education England/ Genomics England Genomic Medicine Fellow, Department of Oncology, University of Oxford
15:15 – 15:45 The use of maternal plasma DNA to diagnose sickle cell disease in the baby
Dr Anthony Cutts
Postdoctoral Researcher, Department of Oncology, University of Oxford
15:45 – 16:00 Coffee
16:00 – 16:45 ctDNA in lymphoma and CLL
Dr Davide Rossi
Deputy Head, Division of Hematology, The Oncology Institute of Southern Switzerland IOSI; Head of the Laboratory of Experimental Hematology, The Institute of Oncology Research IOR, Bellinzona, Switzerland
16:45 – 17:00 Closing Remarks
Professor Anna Schuh
Associate Professor, Director of Molecular Diagnostics, Honorary Consultant Haematologist, Department of Oncology, University of Oxford

 

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.